Development of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors as the cell-cycle progression targets have changed the treatment paradigm for hormone-receptor(HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative HR+/HER2- advanced breast cancer. Ribociclib a selective small-molecule inhibitor of CDK4/6 have shown significantly improved outcomes, especially better progression-free survival outcomes in patients with HR+/HER2- advanced breast cancer. 1 Reference: Slamon D, et al., New England Journal of Medicine. 2020;382(2):514-524.
Novartis and Docplexus have organized an interactive webinar on 10 th October 2020 from 07:30 PM onwards. In this webinar, Dr. T. Raja will discuss “The Proven Strategy for Overall Survival in HR+/HER2- Advanced Breast Cancer.” We invite you to submit your questions which will be answered by the speaker at the end of the session.…
